AUA 2025 Annual Meeting Highlights
Focus on OAB and BPH
Minimally-invasive catheter system makes significant strides in tackling benign prostatic hyperplasia
Over the past decade, the therapeutic landscape of benign prostatic hyperplasia (BPH) has been redefined by minimally invasive therapies that provide rapid symptom relief, decrease the rates of complications, and preserve sexual function. Among these, the Optilume BPH catheter system has emerged as a viable method of managing lower urinary tract symptoms associated with BPH. The Optilume procedure combines mechanical dilation of the prostatic urethra with localized delivery of paclitaxel to maintain long-term urethral patency and improve urine flow.
April 30, 2025
Read more
Vibegron scores high among patient preferences as a treatment option for overactive bladder
Real-world results from a phase 4 study presented at the 2025 Annual Meeting of the American Urological Association (AUA 2025) in Las Vegas, Nevada showed that individuals treated with vibegron for overactive bladder (OAB) symptoms continued to adhere to therapy after 12 months and were satisfied with the levels of symptom relief achieved with this medication.
April 30, 2025
Read more
Hypersensitivity disorders worsen urinary symptoms associated with overactive bladder
Women with overactive bladder (OAB) affected by central sensitization have more severe urinary symptoms and a lower quality of life compared with other patients with OAB, according to a study presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
April 30, 2025
Read more
Prostatic urethral lift proves superior to pharmacotherapy in alleviating symptoms of benign prostatic hyperplasia
Prostatic urethral lift (PUL) provided more substantial improvements in symptoms and quality of life compared to pharmacotherapy for most patients with benign prostatic hyperplasia (BPH) enrolled in the IMPACT trial.
PUL is a minimally invasive procedure that is used to treat lower urinary tract symptoms (LUTS) associated with BPH. During the procedure, small implants are placed into the prostate to pull the prostate tissue away from the urethra, improving urinary flow. PUL is a relatively new treatment option that has shown promise in BPH cases that do not respond to pharmacotherapy.
April 30, 2025
Read more
Men with benign prostatic hyperplasia may still need medications after water vapor therapy
Long-term results from a real-world analysis presented at the 2025 Annual Meeting of the American Urological Association (AUA 2025) in Las Vegas, Nevada revealed a high rate of medication resumption among men who underwent water vapor therapy for benign prostatic hyperplasia (BPH) at a clinic in Southern California.
April 30, 2025
Read moreRelated Articles
A novel prostatic urethral stent shows promise in the treatment of benign prostatic hyperplasia
A nitinol-based stent that is currently under investigation in the United States may soon redefine minimally invasive treatment of benign prostatic hyperplasia (BPH), according to first-time results from a phase 3 randomized, sham-controlled clinical trial. Steven Kaplan, MD, a professor of urology at the Icahn School of Medicine at Mount Sinai, in New York City, presented 12-month outcomes from the ProVIDE study at the 2025 Annual Meeting of the American Urological Association (AUA 2025) in Las Vegas, Nevada.
April 28, 2025
Read more
Bladder regulatory peptides hold potential as add-on therapy for overactive bladder symptoms
Low-molecular bioregulatory peptides extracted from bovine bladder tissue may represent a safe and effective add-on therapy for people with benign prostatic hyperplasia (BPH) who experience overactive bladder (OAB) symptoms that are unresponsive to conventional treatments, according to a study presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
April 28, 2025
Read more
Lipoprotein levels may predict the risk of benign prostatic hyperplasia in middle-aged and older adults
Future strategies for the prevention and management of benign prostatic hyperplasia (BPH) in older men may factor in lipid-related pathways, according to findings presented in a poster session at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
April 28, 2025
Read more
Innovations in the surgical management of BPH safeguard sexual health
When considering surgical treatment for benign prostatic hyperplasia (BPH), patients and providers must weigh the potential improvement in urinary symptoms against multiple factors, including the risk for postprocedural sexual dysfunction. The new standard of care should include counseling men with BPH who are sexually active on available treatment options as well as the potential risks to sexual health, said Kevin Zorn, MD.
April 28, 2025
Read more
Vibegron provides long-term improvement in urinary symptoms associated with overactive bladder
Long-term safety and efficacy data showed that vibegron is a safe, effective add-on therapy for men with benign prostatic hyperplasia (BPH) who continue to experience overactive bladder (OAB) symptoms despite conventional treatment with alpha-blockers. David Staskin, MD, an associate professor of urology at Tufts University School of Medicine, in Boston, presented new findings from the open-label extension phase of the COURAGE trial at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
April 29, 2025
Read more
Quality-of-care gaps persist in the management of women with urinary incontinence in primary care practices
Although primary care physicians provide the first line of defense against urinary incontinence (UI), this condition, which affects quality of life for many women, is not adequately managed in primary care, according to findings from a multicenter study conducted in Kansas and Southern California.
April 29, 2025
Read more
Minimally invasive therapies for overactive bladder are underutilized across the United States
An analysis presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada showed that the use of minimally invasive therapies for overactive bladder (OAB) remains low across the United States, with neuromodulation registering a steady decline over the past decade. First-line therapies for OAB include behavioral changes and pharmacotherapy. When patients with OAB do not achieve significant symptom relief, they can turn to a myriad of minimally invasive therapies (MITs), including bladder botox (BB), tibial nerve stimulation (TNS), and sacral neuromodulation (SNM). While neuromodulation has emerged as a promising treatment option for OAB, with a favorable safety profile, uptake has remained relatively low compared to other treatments.
April 29, 2025
Read more
Rapid symptom improvement remains elusive for individuals treated for benign prostatic hyperplasia
An analysis of real-world outcomes recorded for nearly 20,000 individuals treated for benign prostatic hyperplasia (BPH) showed that patients tend to experience less than expected improvement in symptoms in the first few months following surgical treatment or the initiation of pharmacotherapy for BPH. Claus Roehrborn, MD, Chair of the Department of Urology at UT Southwestern Medical Center, in Dallas, Texas, presented the findings at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
April 29, 2025
Read more
Minimally invasive surgical therapies for benign prostatic hyperplasia have low retreatment rates
Advancements in minimally invasive surgical therapies (MISTs) for benign prostatic hyperplasia (BPH) provide durable benefit and may limit the need for retreatment, according to a systematic review of more than 50 studies presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas, Nevada.
Apr 29, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.